Morphosys has named Jennifer Herron President of MorphoSys US Inc. to build up sales presence overseas.
The Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.
EuropaBios Executive Board and General Assembly of Members this week confirmed the appointment of Tjerk de Ruiter as Chairman of the association.
Symcel has announced the appointment of two new board members; Erik Walldén and Stefan Löfås. Both will play a key role in the companys corporate strategy to grow business in the research market and develop solutions for clinical diagnostics.
Silence Therapeutics plc, a company active in the development of RNA therapeutics, has announced the appointment of Dave Lemus to its Board as Non-Executive Director.
Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.
T cell therapy developer Crescendo Biologics Ltd (Crescendo) has named Eva-Lotta Allan Non-Executive Director of the company. The former CFO of Immunocore brings in over 30 years experience in the biopharmaceutical industry, with special expertise in strategic partnerships with Big Pharma. The Board member of the British Industry Organisation (BIA) is currently a non-executive director for cancer immunotherapy specialist Targovax ASA which recently announced new patents for its colon cancer RAS-targeting candidate drug TG02. Prior to Immunocore, Eva-Lotta was Chief Business Officer at Ablynx NV.
Forbion, a European life science venture capital firm, today announces that Dirk Kersten will join as a General Partner on October 1st, 2018.
Cell Medica, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Companys Board of Directors.
Tigenix NV, a biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic stem cells, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of Tigenix effective as of June 15, 2018.